Regentis Biomaterials

Update in progress

RGNT (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Regentis Biomaterials Ltd. is a regenerative medicine company that develops and commercializes tissue repair solutions in the United States. Its Gelrin platform uses a polyethylene glycol diacrylate hydrogel matrix with denatured fibrinogen to support tissue repair. GelrinC is a cell-free, off-the-shelf hydrogel in Phase II trials for knee cartilage injuries. The company was founded in 2004 and is based in Herzliya, Israel.

Company score

Sentiment: 0.55; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.57; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.17; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.36; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive